Judith Pelham - Amgen Insider

Amgen Inc -- USA Stock  

USD 186.11  0.18  0.10%

Independent Director

Ms. Judith C. Pelham is an Independent Director of Amgen Inc. She is the President Emeritus of Trinity Health, a national system of healthcare facilities, including hospitals, longterm care, home care, psychiatric care, residences for the elderly and ambulatory care, and one of the largest Catholic healthcare systems in the U.S. Prior to her current position at Trinity Health, she was the President and Chief Executive Officer of Trinity Health from 2000 to 2004, the President and Chief Executive Officer of Mercy Health Services, a system of hospitals, home care, longterm care, ambulatory services and managed care, from 1993 to 2000, the President and Chief Executive Officer of the Daughters of Charity Health Services of Austin, a network of hospitals, home care and ambulatory services, from 1982 to 1992, and the Assistant Vice President of Brigham and Womens Hospital from 1976 to 1980. Ms. Pelham was a director of Welltower Inc., a public real estate investment trust for senior living and health care real estate, since May 2012 and serves on its Compensation, Planning, NominatingCorporationrationrate Governance and Investment Committees. Ms. Pelham was a director of Zoll Medical Corporationrationration, a medical products and software solutions company, from February 2011 to April 2012 when it became a wholly owned subsidiary of Asahi Kasei Group. Ms. Pelham was a director of Eclipsys Corporationrationration, a healthcare IT solutions company, from 2009 to August 2010 when it merged with AllScripts, and was a member of its Compensation Committee. In addition, from 2005 to 2006 she was a director of Hospira, Inc., a specialty pharmaceutical delivery company, and a member of its Audit and Public Policy and Compliance Committees. She also sits on the board of trustees of Smith College and is a member of its Audit, Finance, Buildings and Grounds, Executive and Libraries Committees and chairs the Buildings and Grounds Committees.
Age: 69  Director Since 1995      
805 447-1010  www.amgen.com

Management Efficiency

The company has return on total asset (ROA) of 8.27 % which means that it generated profit of $8.27 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 26.43 % meaning that it created $26.43 on every $100 dollars invested by stockholders.
The company currently holds 35.06 B in liabilities with Debt to Equity (D/E) ratio of 110.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has Current Ratio of 6.08 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Haiyuan LoQuintiles IMS Holdings Inc
2015
Samuel ScottAbbott Laboratories
2007
Michael HyattEndo International plc
N/A
Ron TaylorAllergan plc
2013
John ConnaughtonQuintiles IMS Holdings Inc
2008
Ronald TaylorAllergan plc
2013
Arthur HigginsEndo International plc
2013
Sally BlountAbbott Laboratories
2011
Margaret McGlynnVertex Pharmaceuticals Incorpor
2011
Ari BousbibQuintiles IMS Holdings Inc
2016
Elaine UllianVertex Pharmaceuticals Incorpor
2011
Peter McDonnellAllergan plc
2015
Roxanne AustinAbbott Laboratories
2000
Todd SisitskyQuintiles IMS Holdings Inc
2016
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
2015
Mireille GillingsQuintiles IMS Holdings Inc
2013
Phebe NovakovicAbbott Laboratories
2010
Jonathan CosletQuintiles IMS Holdings Inc
2003
James FarrellAbbott Laboratories
2006
Joseph BoccuziAllergan plc
2017
Terrence KearneyVertex Pharmaceuticals Incorpor
2011

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 17,900 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Amgen Inc to your portfolio

Top Management

Amgen Inc Leadership Team
Frank Herringer, Director
R Williams, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance

Amgen Performance Indicators